Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 5/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.61 |
| ▸ | DRD2 | P14416 | 3/20 | 0.59 |
| ▸ | DRD1 | P21728 | 3/20 | 0.59 |
| ▸ | DRD5 | P21918 | 3/20 | 0.59 |
| ▸ | DRD3 | P35462 | 3/20 | 0.59 |
| ▸ | HTR7 | P34969 | 2/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29564708 | 0.90 | CYP2D6 (0.64) | CYP2D6CYP1A2HSD17B10CYP2C9ALOX15 | |
| SCHEMBL25192385 | 0.90 | CYP2D6 (0.64) | CYP2D6CYP1A2HSD17B10CYP2C9ALOX15 | |
| SCHEMBL12083125 | 0.89 | CYP1A2 (0.78) | CYP2D6CYP1A2HSD17B10CYP2C9ALOX15 | |
| SCHEMBL31033047 | 0.87 | CYP2D6 (0.59) | CYP2D6CYP1A2HSD17B10CYP2C9ALOX15 | |
| SCHEMBL16624099 | 0.85 | HTR7 (0.58) | CYP2D6CYP1A2HSD17B10CYP2C9ALOX15 | |
| SCHEMBL25183522 | 0.84 | HTR7 (0.56) | CYP2D6CYP1A2HSD17B10CYP2C9ALOX15 | |
| SCHEMBL17993840 | 0.83 | HTR7 (0.55) | CYP2D6CYP1A2HSD17B10CYP2C9ALOX15 | |
| SCHEMBL18034956 | 0.81 | KDM4E (0.66) | CYP2D6CYP1A2HSD17B10CYP2C9ALOX15 | |
| SCHEMBL25192202 | 0.81 | CYP2D6 (0.53) | CYP2D6CYP1A2HSD17B10CYP2C9ALOX15 | |
| Fumaric Acid SCHEMBL25201865 | 0.80 | HTR7 (0.53) | CYP2D6CYP1A2HSD17B10CYP2C9ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025006077-A2 | ANXIOLYTIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING ANXIETY AND OTHER DISORDERS | MIRALOGX LLC (US) | 2025-01-02 | — | — | WO | claimed |
| US-20240309009-A1 | Anxiolytic Compounds, Pharmaceutical Compositions, and Methods of Treating Anxiety and Other Disorders | MIRALOGX LLC | 2024-09-19 | — | — | US | claimed |
| WO-2025006077-A2 | ANXIOLYTIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING ANXIETY AND OTHER DISORDERS | MIRALOGX LLC (US) | 2025-01-02 | — | — | WO | disclosed |
| US-20240309009-A1 | Anxiolytic Compounds, Pharmaceutical Compositions, and Methods of Treating Anxiety and Other Disorders | MIRALOGX LLC | 2024-09-19 | — | — | US | disclosed |
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240309009-A1 | Anxiolytic Compounds, Pharmaceutical Compositions, and Methods of Treating Anxiety and Other Disorders | OPRD1, OPRK1, OPRM1 | CYP2D6 861/4885CYP1A2 758/4885HSD17B10 506/4885 |
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1I, CACNA1G, CACNA1H | CYP2D6 821/4885CYP1A2 1560/4885HSD17B10 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.